Business Wire

Tsing Hua University Hospital Preparatory Office Officially Opens in Taoyuan

22.9.2022 12:00:00 EEST | Business Wire | Press release

Share

On August 20, the Tsing Hua University Hospital Preparatory Office was officially opened in the Xinkong Building at the Taoyuan Metro Corporation’s Qingpu Depot, which is only one MRT station away from the site where the Hospital will be built.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005421/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

At the opening ceremony (right to left): NTHU senior vice presidents Tai Nyan-hwa and Lyu Ping-chiang, NTHU president W. John Kao, Taoyuan City mayor Cheng Wen-tsan, former NTHU president Hocheng Hong, Taoyuan Metro chairman Liu Kun-I, and Taoyuan Aerotropolis chairman Chen Si-jhen. (Photo: National Tsing Hua University)

NTHU and the Taoyuan City Government have already signed a letter of intent outlining their plan to jointly establish a world-class medical center that will serve the local community; the plan also includes assistance in the training of bilingual teachers and support for science education and experimental education at Taoyuan’s kindergartens, primary, and secondary schools.

The Preparatory Office was officially inaugurated by Taoyuan City mayor Cheng Wen-tsan and NTHU president W. John Kao.

Mayor Cheng has played a key role in the early stages of the Hospital project. He pointed out that Taiwan is good at both electronics and medical care, both of which are taught at NTHU, and that’s why he has been such a staunch supporter of NTHU through all the difficulties which have arisen in the planning stage.

Cheng emphasized that it will take only ten minutes for an ambulance to go from the Taoyuan International Airport to the emergency room at the new hospital; and that in addition to cosmetic surgery and health examinations, the Hospital will also provide critical care and boron neutron capture therapy (BNCT).

Moreover, the Hospital is expected to become a leading center for the development of advanced cell regeneration technology.

President Kao said that this is a very important day for NTHU, in that the school has long had its sights set on medical education, and now the dream has finally come true, noting that “Today is a new milestone in this 50-kilometer journey from NTHU to Taoyuan, which has been going on for some 66 years.”

Kao also noted that this year could be seen as the “year of medicine” at NTHU, since the first batch of medical students has recently been enrolled.

The Hospital will be located near the Hengshan Station (A16) of the Airport MRT line, on a parcel of land provided by Taoyuan City. The size of the parcel is 7.2 hectares, of which 5 hectares will be used for the Hospital itself, while the remaining 2.2 hectares will be used for the affiliated teaching and research facilities.

NTHU senior vice president Lyu Ping-chiang said that the BOT agreement will be finalized by the end of this year, and that construction will start next year, soon after the parcel is transferred. The Hospital is expected to be completed by the end of 2027 and opened in 2028.

The Hospital will initially have 200 general acute care beds, plus an intensive care unit, a respiratory care unit, negative pressure isolation rooms, and a psychiatric unit for both inpatients and outpatients, all of which will be gradually expanded over a number of years to reach a total capacity of 910 beds.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye